QLC7401 not checked

Qilu Pharmaceutical · RBD7022

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“QLC7401 is a small interfering RNA (siRNA) targeting PCSK9. Administered as subcutaneous injection at a specified dose level.”In the company’s words, NCT07450378 on ClinicalTrials.gov
Tested for
Primary Hypercholesterolemia or Mixed Hyperlipidemia (3 trials), Heterozygous Familial Hypercholesterolemia (HeFH), Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Main trialPhase 3
“This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.”In the company’s words, NCT07444086 on ClinicalTrials.gov
Other names
RBD7022

Other drugs for Primary Hypercholesterolemia or Mixed Hyperlipidemia

All 14 drugs for Primary Hypercholesterolemia or Mixed Hyperlipidemia

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 7 Oct 2027 QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
Phase 3Not yet recruiting Dec 2027 QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Phase 3Not yet recruiting Apr 2028 QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2Not yet recruiting Jun 2026 Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
Phase 1Not yet recruiting Jan 2026 Pharmacokinetics and Pharmacodynamics Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow QLC7401

Following is part of Solo: you see every change to QLC7401 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in